期刊文献+

GABRB2基因rs194072和rs187269位点遗传多态性与首发精神分裂症及利培酮疗效的关联性研究 被引量:2

Association between polymorphisms of rs194072,rs187269 in GABRB2 gene and first-episode schizophrenia and the efficacy of risperidone
下载PDF
导出
摘要 目的探讨γ-氨基丁酸β2受体(GABRB2)基因多态性与首发精神分裂症及其利培酮疗效的相关性。方法采用SYBR Green I荧光等位基因特异性实时PCR基因分型法完成277例精神分裂症患者(研究组)和315例正常对照者(对照组)的GABRB2基因rs194072和rs187269两个位点多态性的测定。研究组采用利培酮治疗8周,于治疗前及治疗后第8周末用阳性和阴性综合征量表(PANSS)评估疗效。结果两组rs194072(T/C)和rs187269(T/C)位点的基因型与等位基因频率比较,差异有统计学意义(P<0.05)。研究组CC单倍型频率高于对照组(P=0.003),TT单倍型频率低于对照组(P=0.004)。rs187269位点利培酮治疗有效组与无效组在基因型(P=0.003)与等位基因(P=0.004)频率的差异有统计学意义。结论 GABRB2基因rs194072和rs187269多态性可能与首发精神分裂症有关联,rs187269与利培酮片治疗的个体化差异有关联。 Objective To explore the association between polymorphisms of Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2 ) gene and first-episode schizophrenia,as well as the association with efficacy of risperidone.Methods Polymorphisms of rs194072 and rs187269 in GABRB2 gene was genotyped by using a SYBR Green based real time PCR assay in 277 schizophrenic patients (study group)and 315 healthy controls (control group).Patients in study group were treated with risperidone for 8 weeks and were assessed with Positive and negative Syndrome Scale (PANSS)at baseline and at the end of the treatment.Results There were significant differences in genotypic frequency and allelic frequency of rs194072 (χ2 =7.93,8.64 respectively;P =0.02,0.003 respectively)and rs187269 (χ2 =9.79,8.23 respectively;P =0.008,0.004 respectively) between study group and control group.The haplotype frequency of CC in study group was significantly higher than that in control group (P =0.003)and the haplotype frequency of TT in study group was significantly lower than that in control group (P =0.004).There were significant differences in distribution of genotypes and alleles of rs187269 between patients response to risperidone and patients invalid to risperidone (P =0.003,0.004 respectively).Conclusion The polymorphisms of rs194072 and rs187269 in GABRB2 gene are likely associated with the pathogenesis of schizophrenia and polymorphism of rs187269 is likely associated with the efficacy of risperidone.
出处 《精神医学杂志》 2015年第2期123-126,共4页 Journal of Psychiatry
关键词 首发精神分裂症 利培酮 疗效 基因多态性 γ-氨基丁酸β2受体 First-episode schizophenia Risperidone Efficacy Polymorphism GABRB2
  • 相关文献

参考文献3

二级参考文献26

  • 1吴仁容,李乐华.新型抗精神病药:阿立哌唑[J].国外医学(精神病学分册),2004,31(3):177-179. 被引量:380
  • 2张存贵,魏炳愿,张蕊.阿立哌唑治疗精神分裂症临床观察[J].临床心身疾病杂志,2005,11(3):223-224. 被引量:13
  • 3张光勇,王玉秀,刘从敏.阿立哌唑治疗精神分裂症病人的疗效观察[J].四川精神卫生,2005,18(3):150-151. 被引量:40
  • 4左笑丛,刘世坤,朱运贵,邓孟先,李焕德.阿立哌唑的血药浓度与其治疗精神分裂症疗效的相关性分析[J].中国新药与临床杂志,2006,25(8):601-605. 被引量:13
  • 5Lewontin R. On measures of gametic disequilibrium. Genetics 1988; 120:849-52.
  • 6Chen WY, Shi YY, Zheng YL, et al. Case-control study and transmission disequilibrium test provide consistent evidence for association between schizophrenia and genetic variation in the 22q11 gene ZDHHC8. Hum Mol Genet 2004; 13:2991-5.
  • 7Shi Y, Zhao X, Yu L, et al. Genetic structure adds power to detect schizophrenia susceptibility at SLIT3 in the Chinese Han population. Genome Res 2004; 14:1345-9.
  • 8Zhao X, Shi Y, Tang J, et al. A case control and family based association study of the neuregulinl gene and schizophrenia. J Med Genet 2004; 41:31-4.
  • 9Guo S, Shi Y, Zhao X, et al. No genetic association between polymorphisms in the AMPA receptor subunit GluR4 gene (GRIA4) and schizophrenia in the Chinese population. Neurosci Lett 2004; 369:168-72.
  • 10Yang MS, Yu L, Guo TW, et al. Evidence for association between single nucleotide polymorphisms in T complex protein 1 gene and schizophrenia in the Chinese Han population. J Med Genet 2004; 41:e63.

共引文献393

同被引文献64

  • 1Andreasen NC. Positive vs. negative schizophrenia: a critical evaluation[ J ]. Schizophr Bull, 1985, 11 (3) : 380 - 389.
  • 2劳拉,布兰多,罗梅乌,等.脑磁共振波谱成像[M].天津:天津科技翻译出版公司,2005:1-9.
  • 3Brugger S, Davis JM, Leucht S, et al. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis [ J ]. Bio Psychiatry, 2011, 69(5): 495-503.
  • 4Maddock R J, Buonocore MH. MR Spectroscopic studies of the brain in psychiatric disorders [ J ]. Curr Top Behav Neurosci, 2012, 11 : 199 -251.
  • 5Agarwal N, Port JD, Bazzocchi M, et al. Update on the use of MR for assessment and diagnosis of psychiatric diseases [J~. Radiology, 2010, 255(1): 23-41.
  • 6Ross A J, Sachdev PS. Magnetic resonance spectroscopy in cognitive research[ J]. Brain Res Brain Res Rev, 2004, 44 (2-3): 83-102.
  • 7Brooks WM, Wesley MH, Kodituwakku PW, et al. 1 H- MRS differentiates white matter hypefintensities insubcortical arteriosclerotic encephalopathy from those in normal elderly [ J ]. Stroke, 1997, 28 (10) : 1940 - 1943.
  • 8Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings -part II[J]. Biol Psychiatry, 2000, 48 (5) : 369 - 380.
  • 9Szulc A, Galinska B, Tarasow E, et al. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy ( 1H MRS) [ J~. Pharmacopsyehiatry, 2005, 38 (5) : 214 - 219.
  • 10Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and recta-analysis ~ J ]. Neuropsychopharmaeology, 2005, 30 ( 11 ) : 1949 - 1962.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部